Friday, August 25, 2017

August 23, 2017

Specialty Pharmacy To Pay $13M To Settle False Claims Suit Over Chelation Drug

NEW YORK — Specialty pharmacy US Bioservices Corp. (US Bio) will pay $13.4 million to settle the federal government’s allegations about US Bio’s role in a Novartis Pharmaceuticals Corp. scheme to reward pharmacies for the number of prescriptions they filled for Novartis’ Exjade iron chelation drug, according to a letter filed Aug. 22 with a New York federal court (United States v. US Bioservices Corp., No. 17-6353, S.D. N.Y.).
Post a Comment